Céréa Capital has sold it stake in BCF Life Science, a French specialist in the extraction of natural amino acids, with sales of roughly EUR30 million in 2017, to MBO Partenaires and the company’s senior management team.
Jacques Pidoux and Renaud Sergheraert, Managers of BCF Life Sciences, says: “Céréa Capital’s support since 2012 has been extremely positive in helping to strengthen the company’s industrial facilities and its economic fundamentals. The arrival of MBO Partenaires opens a new page to further accelerate the strategy of innovation and international development whilst ensuring the ongoing pursuit of industrial investments essential to the Group’s growth.”
Gilles Sicard, Executive Managing Director of Céréa Capital, adds: “What attracted us in BCF Life Sciences is the high-quality traceability of its products with multiple applications in health, nutrition or beauty, as well as managers very implicated in development of a global strategy from Pleucadeuc. We wish them continued success with MBO Partenaires.”
Xavier de Prévoisin, Partner with MBO Partenaires, adds: “BCF Life Sciences is a highly innovative company with a strong international based. By investing in its R&D, commercial and industrial resources, we will accelerate its growth and position with high value-added products. We are delighted to accompany BCF Life Sciences and its management in this new phase.”
